Research-grade vs prescription GLP-1: what the difference means

Approved prescription semaglutide and tirzepatide products went through FDA review of their safety, effectiveness and manufacturing quality before they reached patients. Research-grade material is not that product. FDA says unapproved versions of these two drugs have not been through the same review, and the practical difference is not the wording on a vial. It is whether anyone independent has checked what is inside it, and whether the seller can be held to a standard.

What FDA review covers, and what it does not

FDA's review of an approved drug looks at safety, effectiveness and quality. For Zepbound, the tirzepatide product approved for chronic weight management on November 8, 2023, the agency relied on two randomized, double-blind, placebo-controlled trials. Those trials measured weight after 72 weeks in 2,519 adults who received Zepbound and 958 who received placebo. The label, including its warnings, is the output of that review.

Compounded versions sit in a different category. FDA says a compounded drug may be appropriate when a patient's medical need cannot be met by an FDA-approved drug, but compounded drugs are not FDA approved. The agency does not review them for safety, effectiveness or quality before they are marketed. FDA also recommends that patients get a prescription from their doctor and fill it at a state-licensed pharmacy.

The "for research purposes" label

FDA has warned companies that sold unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide labeled "for research purposes" or "not for human consumption." According to FDA, these products were sold directly to consumers for human use, in some cases with dosing instructions, and the agency describes their quality as unknown. A label does not change what is in the vial. It cannot establish identity, strength or sterility, and FDA lists counterfeit, mislabeled and fraudulent products among the risks of the same online market.

The label also does not make every compound legal to sell. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs, and have not been found safe and effective for any condition.

What the adverse event counts can and cannot show

As of May 31, 2026, FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. The agency notes that state-licensed pharmacies that are not outsourcing facilities are not required to report adverse events to FDA, so the true number is probably higher. FDA also says many of the reported events look like those reported for approved products, and that it is not always possible to tell whether the drug caused an event.

Counts like these show that problems happen and that reporting is incomplete. They do not give a rate, because the report does not say how many people use these products. Case reports add detail that a count cannot. A 2026 case report in Cureus describes euglycemic ketoacidosis, a serious metabolic complication that occurs with normal blood glucose, in a non-diabetic 18-year-old who had started semaglutide bought online. The authors point to uncertain dosing and purity of unregulated products as possible contributors. This is one patient, so it shows what can happen, not how often.

What independent testing has found so far

A preprint by Mendias and Awan, posted in April 2026 and not yet peer reviewed, analyzed 6,441 samples of 14 research peptides from a publicly available independent testing dataset. The compounds included semaglutide, tirzepatide, retatrutide, cagrilintide and survodutide. The authors applied two quality frameworks. One approximated standards for compounded medicines, and the other used the stricter standards applied to approved peptide drugs. Depending on the framework, 41.6% to 71.1% of samples failed basic quality criteria, and measurable endotoxin contamination appeared in 15% of samples.

The preprint has limits that matter for interpretation. It pools results across 14 compounds and many sellers, so it does not rank any individual supplier. The dataset comes from consumer-directed testing, and the authors themselves say that kind of testing captures only a small part of the safety profile for people injecting these preparations. A 2026 narrative review in Cureus reaches a similar conclusion from the clinical side: the identity, purity, potency and sterility of these products are uncertain, and the reporting systems that would catch problems are weak. A review synthesizes existing reports and does not generate new measurements.

What the approved label says

Approved products are not risk-free, and their labels carry their own warnings. FDA's Zepbound announcement notes that the drug causes thyroid C-cell tumors in rats and that it is unknown whether it causes such tumors, including medullary thyroid cancer, in humans. Those statements are part of the record a physician reviews with a patient. A research-grade vial comes with no such record, which is the main practical difference. For a side-by-side look at the approved drugs' weight-change data, see the semaglutide vs tirzepatide head-to-head analysis.

Bottom line

Approved prescription products exist for semaglutide and tirzepatide. Research-grade material is not the approved product. FDA says unapproved versions are not reviewed for safety, effectiveness or quality, and its adverse event counts and the independent testing data point the same way. Anyone seeking weight-management treatment should talk to a physician, who can discuss prescription options and whether they fit. The semaglutide and tirzepatide profiles on this site cover the pharmacology of each compound. Verification date for every regulatory statement in this article: October 6, 2026.